Journal
EXPERT OPINION ON DRUG DISCOVERY
Volume 6, Issue 7, Pages 713-724Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/17460441.2011.575777
Keywords
adenosine; brain homeostasis; drug resistance; epilepsy; gene therapy; stem cells
Categories
Funding
- National Institutes of Health (NIH) [R01NS061844, R01NS065957]
- NCRR, a division of the NIH [2P20RR017699]
- Legacy Foundations
- CHDI
Ask authors/readers for more resources
Areas covered: A thorough review of the recent literature on pharmacoresistance in epilepsy was completed and select examples were chosen to highlight the mechanisms of pharmacoresistance in epilepsy and to demonstrate how those mechanistic findings might lead to improved treatment of pharmacoresistant epilepsy. The reader will gain a thorough understanding of pharmacoresistance in epilepsy and an appreciation of the limitations of conventional drug development strategies. Expert opinion: Conventional drug development efforts aim to achieve specificity of symptom control by enhancing the selectivity of drugs acting on specific downstream targets; this conceptual strategy bears an undue risk of development of pharmacoresistance. Modulation of homeostatic bioenergetic network regulation is a novel conceptual strategy to affect whole neuronal networks synergistically by mobilizing multiple endogenous biochemical and receptor-dependent molecular pathways. In our expert opinion section, we conclude that homeostatic bioenergetic network regulation might thus be used as an innovative strategy for the control of pharmacoresistant seizures. Recent focal adenosine augmentation strategies support the feasibility of this strategy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available